Int Ophthalmol (2018) 38:1021–1025 https://doi.org/10.1007/s10792-017-0553-z ORIGINAL PAPER Intravitreal erythropoietin injection in late-stage optic neuropathy: a safety study on human . . . . Ugur Acar Bekir Kucuk Mehmet Koray Sevinc Seckin Aykas Mesut Erdurmus Gungor Sobaci Received: 12 October 2016 / Accepted: 10 May 2017 / Published online: 19 May 2017 Springer Science+Business Media Dordrecht 2017 Abstract Results The mean age of the patients was Aim To evaluate the whether intravitreal erythropoi- 52.38 ± 12.00 years; 2 (12.50%) of them were etin (EPO) administration has any beneﬁcial or female, and 14 (87.50%) of them were male. The adverse effect in patients with late-stage optic neu- mean BCVA levels of 16 patients with optic atrophy ropathy (ON) or not. were 1.12 ± 0.25 logMAR at the initial examination Methods The study examined 16 eyes of 16 patients and 1.08 ± 0.26 logMAR at the ﬁnal visit who had late-stage ON and C1/20 best-corrected (p = 0.102). There was no statistically signiﬁcant visual acuity (BCVA) in their affected eye. There were difference between the initial and ﬁnal RNFL thick- nonarteritic ischemic ON in 10 (62.5%) eyes, trau- nesses, IOP values, p-ERG or p-VEP responses. matic ON in 4 (25.0%) eyes and
International Ophthalmology – Springer Journals
Published: May 19, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud